Compare Sana Biotechnology Inc (SANA) vs US Bancorp (USB) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Sana Biotechnology Inc vs US Bancorp — how do they compare? Sana Biotechnology Inc trades at $3.76 (market cap $1.13B), while US Bancorp trades at $64.99 (market cap $100.17B). The key difference: US Bancorp is far larger — about 88.6× Sana Biotechnology Inc's market cap, and US Bancorp pays a 3.24% dividend while Sana Biotechnology Inc pays none. Which is the better fit depends on your goals.
| SANA | USB | |
|---|---|---|
Market Cap | $1.13B | $100.17B |
Sector | Health | Financials |
52-Week High | $5.92 | $64.47 |
52-Week Low | $2.68 | $45.28 |
Enterprise Value | $1.05B | — |
Dividend Yield | — | 3.24% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
SANA Biotechnology trades at $3.77, up 4.43% today, with a bullish technical signal from moving averages and ADX indicators. The company reported a net loss of $244.17 million for 2025, with negative cash flow from operations, but analyst consensus is strongly positive with 82% buy ratings. Recent news highlights clinical data presentations and a $9.50 average price target from brokerages as of July 30, 2026.
The outlook hinges on clinical progress driving future profitability, but high cash burn and negative ROE pose significant risks. Upside potential exists if pipeline milestones are met, supported by institutional optimism, though investors face volatility from earnings misses and funding needs.
U.S. Bancorp (USB) trades at $64.80, up 0.95% today, with a bullish technical trend and strong support at $64. The company reported Q2 2026 EPS of $1.35, beating estimates, and maintains a net income margin of 27.61%. Recent news highlights institutional buying and upbeat Q2 results, reinforcing positive sentiment.
The outlook is positive with a consensus price target of $70.27, indicating potential upside. Risks include rising interest rate sensitivity and competitive pressures. Earnings growth and dividend stability support a favorable investment case, though macroeconomic factors warrant monitoring.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Sana Biotechnology Inc
Sana Biotechnology Inc. is a clinical-stage biopharmaceutical company focused on creating and delivering engineered cells as medicines for patients. The company is developing cell therapies for various diseases, including oncology, diabetes, and central nervous system disorders. Sana's core strategy is built around two key technological platforms: in vivo gene delivery to repair cells inside the body and ex vivo cell engineering for therapeutic use.
Read more on SANA →About US Bancorp
As a diversified financial-services provider, U.S. Bancorp is one of the nation's largest regional banks, with branches in well over 20 states, primarily in the Western and Midwestern United States. The bank offers many services, including retail banking, commercial banking, trust and wealth services, credit cards, mortgages, and other payments capabilities.
Read more on USB →
